We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amneal (AMRX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
Wall Street analysts expect Amneal Pharmaceuticals (AMRX - Free Report) to post quarterly earnings of $0.13 per share in its upcoming report, which indicates a year-over-year decline of 31.6%. Revenues are expected to be $693.68 million, up 11.9% from the year-ago quarter.
The current level reflects a downward revision of 3.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Amneal metrics that are commonly tracked and forecasted by Wall Street analysts.
The combined assessment of analysts suggests that 'Net Revenue- Generics Segment' will likely reach $404.71 million. The estimate indicates a change of +3.5% from the prior-year quarter.
The consensus among analysts is that 'Net Revenue- AvKARE Segment' will reach $167.09 million. The estimate points to a change of +26.7% from the year-ago quarter.
Analysts forecast 'Net Revenue- Specialty Segment' to reach $120.20 million. The estimate suggests a change of +23.5% year over year.
Over the past month, shares of Amneal have returned -4.7% versus the Zacks S&P 500 composite's +0.7% change. Currently, AMRX carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amneal (AMRX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Wall Street analysts expect Amneal Pharmaceuticals (AMRX - Free Report) to post quarterly earnings of $0.13 per share in its upcoming report, which indicates a year-over-year decline of 31.6%. Revenues are expected to be $693.68 million, up 11.9% from the year-ago quarter.
The current level reflects a downward revision of 3.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Amneal metrics that are commonly tracked and forecasted by Wall Street analysts.
The combined assessment of analysts suggests that 'Net Revenue- Generics Segment' will likely reach $404.71 million. The estimate indicates a change of +3.5% from the prior-year quarter.
The consensus among analysts is that 'Net Revenue- AvKARE Segment' will reach $167.09 million. The estimate points to a change of +26.7% from the year-ago quarter.
Analysts forecast 'Net Revenue- Specialty Segment' to reach $120.20 million. The estimate suggests a change of +23.5% year over year.
View all Key Company Metrics for Amneal here>>>
Over the past month, shares of Amneal have returned -4.7% versus the Zacks S&P 500 composite's +0.7% change. Currently, AMRX carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>